To track the status of this bill, find it on our Legislation Tracker. Click here to contact the sponsor of the bill to share your thoughts, or click here to email your Senator and Representative about it.
Libertas Institute supports this bill
Under current law, patients generally must have a terminal illness to qualify for access to experimental treatments known as “Right to Try” outside of clinical trials.
Senate Bill 222 by Sen. Chris Wilson addresses that.
This proposal expands Utah’s “Right to Try” law to give seriously ill patients broader access to investigational medicines and devices that have completed initial safety testing. This bill removes the requirement that a patient be terminally ill and instead allows individuals with a physician-certified “eligible illness”—meaning a condition that presents significant risk and limited satisfactory conventional treatment options—to seek investigational drugs or devices that have passed Phase I testing with the U.S. Food and Drug Administration. The bill also updates definitions to clarify what forms of medicine and investigational products are covered under the statute, ensuring modern treatment modalities are included.
By broadening eligibility and streamlining the definitions in state code, SB 222 strengthens patient autonomy and medical decision-making for Utahns facing serious health challenges.
